Claims for Patent: 10,034,916

Summary for Patent: 10,034,916

Title:	Methods of treating a retinal disease by retinal pigment epithelial stem cells
Abstract:	The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.
Inventor(s):	Temple; Sally (Slingerlands, NY), Stern; Jeffrey (Slingerlands, NY), Salero-Coca; Enrique L. (Delmar, NY)
Assignee:	Regenerative Research Foundation (Rensselaer, NY)
Application Number:	13/915,845
Patent Claims:	1. A method for treating a retinal disease or disorder selected from a group consisting of macular degeneration, age-related macular degeneration, retinitis pigmentosa, Leber's hereditary optic neuropathy and cone dystrophy, which method comprises administering, to the retina of a patient, an amount of retinal pigment epithelial stem cells (RPESCs) that is effective for treating the retinal disease or disorder, wherein the RPESCs (a) require growth factors in order to proliferate in serum-free culture conditions; (b) express at least one marker selected from the group consisting of RPE65, Mitf, Cralbp, Otx2 and Bestrophin; (c) express at least one marker selected from the group consisting of SSEA-4, Sox2, KLF4 and c-Myc; (d) are self-renewing and capable of differentiating into a plurality of cell types, including retinal pigment epithelium (RPE) and mesodermal lineages; and (e) do not express any of the markers Chx10, Nanog and Oct4. 2. The method according to claim 1, wherein the retinal disease or disorder is macular degeneration or retinitis pigmentosa. 3. A method for treating a retinal disease or disorder selected from a group consisting of macular degeneration, age-related macular degeneration, retinitis pigmentosa, Leber's hereditary optic neuropathy and cone dystrophy, which method comprises (i) culturing one or more RPESCs isolated from the posterior RPE or descended from one or more RPESCs isolated from the posterior RPE of a mammal under conditions suitable for differentiation, wherein the RPESCs (a) require growth factors in order to proliferate in serum-free culture conditions; (b) express at least one marker selected from the group consisting of RPE65, Mitf, Cralbp, Otx2 and Bestrophin; (c) express at least one marker selected from the group consisting of SSEA-4, Sox2, KLF4 and c-Myc; (d) are self renewing and capable of differentiating into a plurality of cell types, including retinal pigment epithelium (RPE) and mesodermal lineages; and (e) do not express any of the markers Chx10, Nanog and Oct4; and (ii) administering an amount of the differentiated RPESCs to a retina of a patient that is effective for treating the retinal disease or disorder. 4. The method according to claim 3, in which the one or more RPESCs are cultured in the presence of at least one factor selected from the group consisting of nerve growth factor, glial cell-line derived growth factor, neurotrophin 3, neutrophin 4/5, neurotrophin 6, ciliary neurotrophic factor, interleukin 6, interleukin 11, cardiotrophin 1, a growth factor hormone, hyaluronidase, chondroitinase ABC, fibroblast growth factor 2 (FGF2), fibroblast growth factor 8 (FGF8), retinoic acid (RA), N2 supplement, dexamethasone, beta-glycerophosphate, ascorbic acid, ascorbic acid-2-phosphate, BMP2, BMP4, activin, insulin, selenium, epidermal growth factor (EGF), and sonic hedgehog. 5. The method according to claim 4, in which the one or more factors include at least FGF2. 6. The method according to claim 3, in which the retinal disease or disorder is macular degeneration or retinitis pigmentosa. 7. The method according to claim 2 or 6, in which the macular degeneration is age-related macular degeneration. 8. The method according to claim 3, in which the RPESCs isolated from the retina of the patient are cultured under proliferative conditions. 9. The method according to claim 3, in which the RPESCs are differentiated to obtain retinal cells. 10. The method according to claim 3, in which the RPESCs are differentiated to obtain neural cells. 11. The method according to claim 3, in which the RPESCs are differentiated to obtain retinal pigment epithelial (RPE) cells. 12. The method according to claim 3, in which the RPESCs are RPESCs isolated from a retina of the patient.

Details for Patent 10,034,916

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004		2033-06-12
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004		2033-06-12
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2033-06-12